Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • Obesity – Insulin Resistance – Diabetes
    • NASH – Fibrosis
    • Diabetic Nephropathy
    • Fibrosis
    • Diabetic Neuropathy
    • GLP-1 Expertise
    • Immunometabolism
    • Dyslipidaemia Atherosclerosis
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page

South American Pharma customer

by Dominique Alquier | Mar 22, 2022 | temoignages | 0 comments

“Once again, I would like to appreciate for all your assistance during the study execution and all technical issues that Physiogenex experts helped us to understand. Physiogenex is a very strategic partner and in the future, we certainly will consider you to perform our preclinical studies.”

Previous News

Recent News

  • Physiogenex to present its obese NASH hamster model at the NAFLD/NASH Keystone Symposia, Banff, AB, Canada March 19-23, 2023 03/15/2023
  • Physiogenex to present the SDT fatty rat model at the 5th CKD Summit in Boston, MA, March 7-9, 2023 03/06/2023
  • Physiogenex to present its obese NASH hamster model at the Global NASH Congress, London, UK, March 2nd-3rd, 2023 02/27/2023
  • Physiogenex to present its obese NASH hamster model at the 2nd HFpEF Summit in Boston, MA, Jan. 25-26, 2023 01/18/2023
  • Physiogenex is now ISO 9001:2015 certified! 12/27/2022
  • Physiogenex to present its obese NASH hamster model at the 20th World Congress of Insulin Resistance in Los Angeles, CA, Dec 1-3, 2022 11/29/2022

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • NASH Preclinical
  • Dyslipidaemia Atherosclerosis
  • Diabetic Nephropathy
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • Twitter
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT